Cook MyoSite Advances Phase III Cell Therapy Trial for Chronic Fecal Incontinence in Women
Key Insights
Cook MyoSite (search) and Veristat (search) have successfully enrolled over 100 participants across 26 sites in the DigniFI Study, a Phase III trial testing iltamiocel cell therapy for chronic fecal incontinence (search).
The randomized, controlled trial targets women with chronic fecal incontinence (search) caused by obstetric anal sphincter injury (search) during childbirth, addressing an underserved patient population.
The study achieved greater than 95% adherence rates and met critical enrollment milestones, advancing personalized cell therapy for women's health conditions with limited treatment options.
Cook MyoSite (search) has reached a significant enrollment milestone in its Phase III clinical trial evaluating iltamiocel, an investigational cell therapy for chronic fecal incontinence (search) in women. The DigniFI Study, conducted in partnership with clinical research organization Veristat (search), has successfully enrolled more than 100 participants across 26 activated sites with greater than 95% study adherence.
Trial Design and Patient Population
The DigniFI Study is a two-stage, randomized, controlled Phase III trial comparing the safety and efficacy of iltamiocel with placebo in female participants with chronic fecal incontinence (search) and a history of obstetric anal sphincter injury (search) (OASI). Chronic fecal incontinence is characterized by the unintended loss of liquid or solid stool occurring for at least six months, with anal sphincter injury during childbirth representing a common cause in women.
The condition can have profound negative impacts on quality of life for affected women, who represent a historically underserved patient population with extremely limited treatment options.
Addressing Unmet Medical Need
"Cook MyoSite (search) has been researching and advancing personalized cell therapy treatment for women who have historically been underserved," said Ron Jankowski, Cook MyoSite Vice President of Regulatory and Scientific Affairs. "We look forward to seeing the outcome of the study and the potential impact for women suffering from chronic FI in the future."
The partnership with Veristat (search) has been instrumental in achieving this enrollment milestone. Veristat Chief Strategy Officer Cindy Henderson noted that "Cook MyoSite (search) represents the best of clinical development. They are passionate about solving unmet clinical needs for as many patients as possible using the most advanced personalized medical science."
Clinical Development Partnership
Veristat (search), a global clinical research organization specializing in complex studies, has supported Cook MyoSite (search) through its comprehensive clinical trial management approach. The CRO applies advanced biostatistical methods and involves integrated teams of clinical, medical, biostatistical, and regulatory experts throughout the development process.
The company has a track record of supporting regulatory approval for more than 100 therapeutics, including 39 oncology drugs, over 30 years of operation. Veristat (search)'s model focuses on reducing timeline delays to achieve enrollment milestones and enable sponsors to reach market goals while helping more patients access novel therapies.
Future Implications
The successful enrollment milestone represents progress toward addressing a significant unmet need in women's health. The trial's adaptive design and focus on personalized cell therapy reflects the evolving landscape of regenerative medicine approaches for conditions with limited therapeutic options.
As the study continues toward completion, the results could potentially provide new treatment options for women experiencing chronic fecal incontinence (search) related to obstetric complications, a population that has historically faced limited therapeutic alternatives.